Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31628
Title: Mortality under early access to antiretroviral therapy vs . Eswatini’s national standard of care: the MaxART clustered randomized stepped‐wedge trial
Authors: Chao, A.
Spiegelman, D.
Khan, S.
Walsh, F.
Mazibuko, S.
Pasipamire, M.
Chai, B.
Reis, R.
Mlambo, K.
DELVA, Wim 
Khumalo, G.
Zwane, M.
Fleming, Y.
Mafara, E.
Hettema, A.
Lejeune, C.
Baernighausen, T.
Okello, V
Issue Date: 2020
Publisher: WILEY
Source: HIV MEDICINE, 21 (7) , p. 429 -440
Abstract: Objectives Current WHO guidelines recommend the treatment of all HIV-infected individuals with antiretroviral therapy (ART) to improve survival and quality of life, and decrease infection of others. MaxART is the first implementation trial of this strategy embedded within a government-managed health system, and assesses mortality as a secondary outcome. Because primary findings strongly supported scale-up of the 'treat all' strategy (hereafter Treat All), this analysis examines mortality as an additional indicator of its impact. Methods MaxART was conducted in 14 Eswatinian health clinics through a clinic-based stepped-wedge design, by transitioning clinics from then-national standard of care (SoC) to the Treat All intervention. All-cause, disease-related, and HIV-related mortality were analysed using the Cox proportional hazards model, censoring SoC participants at clinic transition. Median follow-up time among study participants was 292 days. There were 36/2034 deaths in SoC (1.77%) and 49/1371 deaths in Treat All (3.57%). Results Between September 2014 and August 2017, 3405 participants were enrolled. In SoC and Treat All interventions, respectively, the multivariable-adjusted 12-month all-cause mortality rates were 1.42% [95% confidence interval (CI): 0.66-2.17] and 1.60% (95% CI: 0.78-2.40), disease-related mortality rates were 1.02% (95% CI: 0.40-1.64) and 1.10% (95% CI: 0.46-1.73), and HIV-related mortality rates were 1.03% (95% CI: 0.40-1.65) and 0.99% (95% CI: 0.40-1.58). Treat All had no impact on all-cause [hazard ratio (HR) = 1.12, 95% CI: 0.58-2.18, P = 0.73], disease-related (HR = 1.04, 95% CI: 0.52-2.11, P = 0.90), or HIV-related mortality (HR = 0.93, 95% CI: 0.46-1.87, P = 0.83). Conclusion There was no immediate benefit of the Treat All strategy on mortality, nor evidence of harm. Longer follow-up of participants is needed to establish long-term consequences.
Notes: Spiegelman, D (corresponding author), Yale Sch Publ Hlth, 60 Coll St, New Haven, CT 06510 USA.
donna.spiegelman@yale.edu
Other: Spiegelman, D (corresponding author), Yale Sch Publ Hlth, 60 Coll St, New Haven, CT 06510 USA. donna.spiegelman@yale.edu
Keywords: antiretroviral therapy;Eswatini;HIV;AIDS;mortality;Treat All
Document URI: http://hdl.handle.net/1942/31628
ISSN: 1464-2662
e-ISSN: 1468-1293
DOI: 10.1111/hiv.12876
ISI #: WOS:000535373100001
Rights: © 2020 British HIV Association
Category: A1
Type: Journal Contribution
Validations: ecoom 2021
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
chao.pdf
  Restricted Access
Published version634.47 kBAdobe PDFView/Open    Request a copy
Show full item record

WEB OF SCIENCETM
Citations

5
checked on Apr 30, 2024

Page view(s)

38
checked on Sep 7, 2022

Download(s)

6
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.